CureVac’s COVID-19 Vaccine Is Safe, But Efficacy Not Yet Disclosed

CureVac BV (NASDAQ: CVAC) said its first-generation COVID-19 vaccine candidate had passed its first interim analysis, but it was not yet ready to share efficacy data.
The company said an independent Data Safety Monitoring Board found no safety concerns for the vaccine, dubbed CV2CoV.
“The trial will continue to collect sufficient data in order to conduct statistically significant efficacy analysis,” the company said in its statement.
The CureVac vaccine is based on mRNA technology, like the ones developed by Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE) – BioNTech SE (NASDAQ: BNTX).
In its Q1 earnings release, the company said CV2CoV data readout from the pivotal Phase 2b/3 trial is expected in June 2021.
Price Action: CVAC shares are down 3.5% at $107.56 during the market session on the last check Tuesday.

See more from Benzinga

Click here for options trades from Benzinga
European Drug Regulator Supports Use Of Pfizer-BioNTech COVID-19 Vaccine In Adolescents: Reuters
India To Skip Local Trials for 'Well Established' COVID-19 Vaccines; Pfizer Shots May Arrive By July: Reuters